SynteractHCR Appoints Vice President of Global Clinical Operations
SynteractHCR has hired Dr. Dieter Seitz-Tutter as vice president, global clinical operations. This new position was established to accommodate the continued growth of the company as SynteractHCR extends its reach supporting the drug development programs of small to mid-sized biopharma companies.
Sietz-Tutter will join the senior management team, helping to proactively ensure proper planning, conduct, patient safety, data quality, and all processes critical to clinical development. He will lead the company’s experienced clinical operations teams while fostering good communication between SynteractHCR, study sites and the sponsor.
“Dieter’s extensive experience in the CRO industry and his knowledge of the global clinical market are very valuable to our clients. He knows the emphasis we place on studies being completed successfully—on time, within budget, and in compliance with regulatory requirements,” said Wendel Barr, CEO. “We are pleased to add his industry and clinical expertise to our seasoned leadership team.”
Seitz-Tutter has more than 25 years of experience in clinical research—20 of which he spent in the CRO industry. Most recently, Seitz-Tutter was vice president of global clinical development at Chiltern where he was responsible for all clinical and country operations outside of North America. He also served as vice president for Europe at Medpace where he was responsible for clinical operations in 17 countries across Europe and Israel. Earlier in his career, he spent 13 years at Kendle where he served in different roles, including director of business development Europe, managing director Germany and vice president global clinical development Europe.
Dr. Seitz-Tutter holds a Master of Science and Doctor of Science degree in biology from Ludwig Maximilian University of Munich. He will work from the SynteractHCR Munich office.
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision ” philosophy and ICD+ approach, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data so clients get to decision points faster.
SynteractHCR expands senior leadership team with appointment of new Vice President of Global Clinical Operations.
Amanda Whitlock, 760-230-2424
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
PHILIP-MORRIS-INTL21.7.2018 20:21 | pressemeddelelse
Philip Morris International Announces Non-Executive Board Chairman Louis Camilleri to Assume CEO Role at Ferrari S.p.A.
LOXAM20.7.2018 16:53 | pressemeddelelse
Loxam Announces a Conditional Agreement to Acquire UK Platforms
SCHLUMBERGER-LIMITED20.7.2018 13:02 | pressemeddelelse
Schlumberger Announces Second-Quarter 2018 Results
FL-H.I.G.-CAPITAL19.7.2018 21:52 | pressemeddelelse
H.I.G. Capital Announces the Sale of KidsFoundation
SIG-COMBIBLOC-GROUP19.7.2018 18:03 | pressemeddelelse
SIG Combibloc Group Holdings S.à r.l.: 2018 Second Quarter Results
FL-NEORIS19.7.2018 17:34 | pressemeddelelse
NEORIS Announces Creation of Innovation Labs Worldwide to Create a Smarter Future
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum